Latest Conference Articles

November 7th 2015, 12:24pm

PER® New York Lung Cancer Symposium

Immune checkpoint inhibitors have demonstrated encouraging results for patients with small cell lung cancer and mesothelioma, which are two aggressive thoracic malignancies with few options.

November 7th 2015, 11:59am

PER® New York Lung Cancer Symposium

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti–PD-1/PD-L1 treatments in lung cancer.

November 7th 2015, 10:36am

PER® New York Lung Cancer Symposium

Dr. Renato G. Martins talks about the impact of nivolumab, an anti–PD-1, and ipilimumab, an anti CTLA-4, in the treatment of lung cancer.

November 7th 2015, 10:11am

LUGPA Annual Meeting

With the emergence of the novel treatments abiraterone acetate (Zytiga) and enzalutamide (Xtandi), urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer patients.

November 7th 2015, 9:59am

LUGPA Annual Meeting

The keynote address at the 2015 LUGPA Annual Meeting urged physicians to band together and create an offensive strategy when it comes to the nation's healthcare system.

November 6th 2015, 4:19pm

LUGPA Annual Meeting

Deepak A. Kapoor, MD, chairman and CEO of Integrated Medical Professionals and Large Urology Group Practice Association's (LUGPA's) chairman of health policy, discusses LUGPA's legislative advocacy efforts.

November 6th 2015, 3:54pm

LUGPA Annual Meeting

Hormone therapies for prostate cancer aimed at reducing serum androgens are trained on the wrong target: the testes and the adrenal glands. Rather, they should attack the prostate cancer cells themselves.

November 6th 2015, 2:32pm

LUGPA Annual Meeting

Raoul S. Concepcion, MD, FACS, director of Advanced Therapeutics at Urology Associates, PC, discusses healthcare's movement away from fee-for-service reimbursements.

November 6th 2015, 1:51pm

LUGPA Annual Meeting

Thomas E. Keane, MD, ChB, discussed combination approaches in treatment-resistant mCRPC at the 2015 LUGPA Annual Meeting.

November 6th 2015, 1:44pm

PER® Chemotherapy Foundation Symposium (CFS)

Adding the MEK inhibitor trametinib to the BRAF inhibitor dabrafenib significantly improves long-term outcomes while lowering certain adverse events associated with either agent alone for patients with BRAF-mutated metastatic melanoma.

November 6th 2015, 12:55pm

LUGPA Annual Meeting

E. David Crawford, MD, discussed issues with FDA standards for ADT agents and current treatment approaches to androgen deprivation in prostate cancer at the 2015 LUGPA Annual Meeting.

November 6th 2015, 12:19pm

PER® Chemotherapy Foundation Symposium (CFS)

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program and Head of Experimental Therapeutics, NYU Langone Medical Center, discusses the significance of the FDA approval of the combination of dabrafenib and trametinib for patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation.

November 6th 2015, 10:43am

PER® Chemotherapy Foundation Symposium (CFS)

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses emerging therapies for patients with triple-negative breast cancer.

November 6th 2015, 6:33am

PER® Chemotherapy Foundation Symposium (CFS)

Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.

November 6th 2015, 6:06am

LUGPA Annual Meeting

Evan R. Goldfischer, MD, MBA, FACS, director of the Research Department at Premier Medical Group of the Hudson Valley, discusses the benefits of integrated medical groups.

November 5th 2015, 2:30pm

PER® Chemotherapy Foundation Symposium (CFS)

The kinase inhibitors sorafenib and lenvatinib have significantly altered the treatment paradigm for patients with advanced radioactive iodine-refractory differentiated thyroid cancer in both older and younger populations.

November 5th 2015, 2:04pm

PER® Chemotherapy Foundation Symposium (CFS)

Patrick I. Borgen, MD, chair, Department of Surgery, head, Brooklyn Cancer Center, Maimonides Medical Center, compares the efficacy of surgical versus medical treatment of patients with breast cancer.

November 5th 2015, 1:47pm

PER® Chemotherapy Foundation Symposium (CFS)

While the prognosis remains good for individuals with HPV-positive oropharyngeal cancers, the incidence of these cancers continues to rise, and researchers are currently seeking less intense treatment options that are equally effective but not as toxic for patients.

November 5th 2015, 12:58pm

PER® Chemotherapy Foundation Symposium (CFS)

The use of neoadjuvant chemotherapy in advanced ovarian cancer continues to increase, even though the practice has not been shown to improve survival versus primary cytoreduction.

November 5th 2015, 12:47pm

PER® Chemotherapy Foundation Symposium (CFS)

Franco Muggia, MD, professor of Medicine, NYU Langone Medical Center, discusses the current status of intraperitoneal therapy for patients with gynecologic malignancies.